Evaluation of cardiac troponin dynamics as an early biomarker for anthracycline-induced cardiotoxicity
- Conditions
- canceroncology10006291
- Registration Number
- NL-OMON56966
- Lead Sponsor
- Sint Antonius Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
- Female
- Age >= 18 years
- Patients that are to be treated for breast cancer in the adjuvant setting
with one of the following treatment schedules, in accordance with SAZ
protocols:
o Doxorubicine and cyclofosfamide q2w for 4 cycles, followed by paclitaxel q1w
for 12 cycles
o Doxorubicine and cyclofosfamide q3w for 4 cycles, followed by paclitaxel q1w
- Informed consent form (ICF) signed prior to participation in the study.
Exclusion Criteria
Patients that already started treatment in one of the above described protocols
are not eligible for inclusion, since a baseline sample is necessary.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method